Shasta Critical Care Specialists

Staff

Harbhajan Singh, MD - Extended Curriculum Vitae

(Biography) Harbhajan Singh, MD
Professional Experience:

2011 – Present:
Private Practice: Pulmonology, Critical Care and Sleep Medicine, Shasta Critical Care Specialists, Redding, CA
2009 – 2011:
Illinois Specialty Physician Services, Peoria IL
2005 – 2009:
Illinois Lung Institute/Peoria Pulmonary Associates, Ltd., Peoria, IL
2000 – 2005:
Covenant Medical Center, Waterloo, IA
1999 – 2000:
East Orange VA Medical Center, Orange, NJ
Education & Training:

1977 - 1982:
Medical School: Government Medical College Patiala, India
1982 – 1989:
Internship & Residency: Government Medical College and Rajindra Medical College & Hospital Patiala, India
1993 – 1996:
Residency: DC General Hospital (Georgetown University) Washington, D.C. and New Jersey Medical School UMDNJ Newark, New Jersey – Internal Medicine
1996 – 1999
Fellowship: University of Medicine & Dentistry (UMDNJ) Pulmonary & Critical Care Medicine
Teaching Experience:

Clinical Assistant Professor, University of Illinois College of Medicine at Peoria, IL

Board Certifications:

  • Certified, American Board of Internal Medicine, Subspecialty: Pulmonary Disease – 2001
  • Certified, American Board of Internal Medicine, Subspecialty: Critical Care Medicine – 2002
  • Certified, American Board of Sleep Medicine, Specialty: Sleep Medicine - 2007
Memberships:

  • American College of Chest Physicians
  • American Thoracic Society
  • American Sleep Disorders Association
Clinical Research:

Co-Investigator Protocol DORI-10: A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Imipenem in Ventilator-Associated Pneumonia (2005-2006)

Co-Investigator Protocol DORI-09: Peninsula DORI – 09: A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Piperacillin/Tazobactam in Hospital-Acquired Pneumonia (2005-2006)

Co-Investigator Altana Pharma BY2001/MI-007: “Venticute® (rSP-C Surfactant) in Patients with Pneumonia or Aspiration of Gastric Contents Leading to Intubation, Mechanical Ventilation, and Severe Oxygenation Impairment, A Randomized, Multinational, Multicenter, Parallel Group, Double Blind, Control Study.” (2005-2008)

Co-Investigator Discovery Laboratories KL4-ARDS-04: “A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Surfaxin® (Lucinactant) Delivered Via Bronchopulmonary segmental Lavage to Standard of Care in Patients with Acute Respiratory Distress Syndrome (ARDS).” (2005-2006)

Co-Investigator GSK LIPOS EMD20001: “A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults.” (2005-2006)

Co-Investigator Takeda TAK 242-011: “A Pivotal, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 In Adults with Severe Sepsis.” (2005-2007)

Co-Investigator Hospira 2001-001: “A Phase 4 Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater than Twenty-Four Hours of Continuous Sedation.” (2005-2007)

Co-Investigator Emphasys Medical, Inc 630-0001: Endobronchial Valve for Emphysema PalliatioN Trial – VENT (2005-2007)

Co-Investigator GSK-OPL 104226: “A prospective observational study for the psychometric validation of a patient-reported questionnaire in acute exacerbation of chronic obstructive pulmonary disease (AECOPD)” (2006)

Co-Investigator Tanox Inc. TNX-832 (Sunol-cH36): “The Safety, Pharmacokinetics, and Pharmacodynamic Effects of TNX-832 (Sunol-cH36) in Subjects with Acute Lung Injury/Acute Respiratory Distress Syndrome” (2006)

Co-Investigator Artisan Protocol Number 2-001: “A Randomized, Double-Blind, Placebo-controlled, Phase 2-B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated intravascular Coagulation.” (2007- 2008)

Co-Investigator Ortho-McNeil Janssen Scientific Affairs, LLC DORIINI2002, “A Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals Where Pseudomonas Aeruginosa May Be Prevalent Pathogen.” (2007- 2008)

Co-Investigator Asthmatx, Inc.: “Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial (Asthma Intervention Research (Air2) Trial) (2006- 2007)

Co-Investigator Eisai Protocol E5564-G000-301: “A Controlled comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis” (2006- Current)

Co-Investigator Broncus Technologies, Inc.: “Ease Study: A Randomized, Double-Blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogenous Emphysema Subjects with Severe Hyperinflation. (2007- Current)

Co-Investigator Altor BioScience CA-ALT-836-01-08: Efficacy and Safety Evaluation of ALT-386 in Patients with Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome (2009-Current)

Co-Investigator CARDS AR06: Calfactant Therapy for Direct Acute RepiratoryDistress Syndrome & Direct injury in Adults and Childtren (2009-Current)

Co-InvestigatorPfizer: Linezolid in The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus (2009-Current)

Co-Investigator Protocol #197-08-250 – Kendle Otsuka: Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy, and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients with Chronic Obstructive Pulmonary Disease Associated with Emphysema (2009-Current)